Anti-CD20-tervezés és B-sejt-depletiós mechanizmusok sclerosis muliplexben

View at publisher Summarise with VIRAT
Authors: Zsolt Illés
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The efficacy of anti-CD20 therapies in multiple sclerosis (MS) has been recognized since 2008. Since then, three anti-CD20 monoclonal antibodies - ocrelizumab, ofatumumab, and ublituximab - have been developed and approved for MS treatment, whereas rituximab, the first monoclonal antibody shown to be effective, remains an off-label therapy in this indication. Anti-CD20 antibodies deplete B cells primarily through two mechanisms: complement-dependent cytotoxicity (CDC) and natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC). The relative contribution of these mechanisms differs among individual antiCD20 antibodies. NK cell-mediated ADCC is modulated by the glycosylation state of the antibody Fc region as well as by genetic polymorphisms in FcγRIIIa, the Fc receptor on NK cells responsible for Fc binding. Fc engineering can enhance ADCC and partially overcome the functional consequences of FcγRIIIa polymorphisms. This article reviews the structure and mechanisms of action of immunoglobulins and anti-CD20 antibodies; outlines the development of antibody humanization and Fc engineering to enhance efficacy and tolerability; presents clinical data from ublituximab treatment; and discusses additional strategies for achieving effective B-cell depletion.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Monoclonal and Polyclonal Antibodies Research T-cell and B-cell Immunology

Publication details

Journal / source
Ideggyógyászati Szemle
Volume
79
Issue
3-4
Pages
131–141
Publication date
30 March 2026
Language
HU